Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1823-1826

  O'Mahony, Rachel ^a   Richards, Alison ^a   Deighton, Chris ^b   Scott, David ^c  

^a ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^b DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; DISEASE COURSE; DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957265767     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.105577     Document Type: Review

References (17)

1. Jobanputra P, Wilson J, Douglas K, et al. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) 2004;43:206-10. (Pubitemid 38219677)
2. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;1:CD006356.
3. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73.
4. Cohen G, Gossec L, Dougados M, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007;66:358-63.
5. Tengstrand B, Larsson E, Klareskog L, et al. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol 2007;36:351-8. (Pubitemid 350034806)
6. Fleischmann RM, Cohen SB, Moreland LW, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin 2005;21:1181-90.
7. Gøtzsche PC, Hansen M, Stoltenberg M, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996;25:194-9.
8. Ahern MJ, Hall ND, Case K, et al. D-Penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984;43:213-17.
9. De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981;40:560-3.
10. Bacon PA, Myles AB, Beardwell CG, et al. Corticosteroid withdrawal in rheumatoid arthritis. Lancet 1966;2:935-7.
11. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987;82:781-6.
12. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
13. Tishler M, Caspi D, Yaron M. Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough? Ann Rheum Dis 1992;51:1330-1. (Pubitemid 23000071)
14. Van der Leeden H, Dijkmans BA, Hermans J, et al. A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis. Clin Rheumatol 1986;5:56-61.
15. GOLD therapy in rheumatoid arthritis. Report of a multicentre control trial. Ann Rheum Dis 1960;19:95-119.
16. Research Sub-Committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multicentre controlled trial. Ann Rheum Dis 1961;20:315-34.
17. Berthelot JM, Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents? Joint Bone Spine 2004;71:257-60. (Pubitemid 39037310)